The stimulator of interferon genes (STING) agonists for treating acute myeloid leukemia (AML): current knowledge and future outlook

Song, Xiaolu; Ye, Peng; Wang, Xiaogang; Chen, Qi; Lan, Xinyu; Shi, Fangfang

doi:10.1007/s12094-022-03065-6

Cited by 5 publications

(2 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a protein localized on the ER membrane, the stimulator of interferon genes (STING) plays a vital role in activating immune responses [116,117]. Cyclic GMP-AMP synthase (cGAS) is a cellular DNA sensor that could recognize pathogen-released cytoplasmic double-stranded DNA (dsDNA).…”

Section: Cytokinesmentioning

confidence: 99%

Innate Immunity in Cancer Biology and Therapy

Zhang

Xue

et al. 2023

IJMS

View full text Add to dashboard Cite

Immunotherapies including adaptive immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cells, have developed the treatment of cancer in clinic, and most of them focus on activating T cell immunity. Although these strategies have obtained unprecedented clinical responses, only limited subsets of cancer patients could receive long-term benefits, highlighting the demand for identifying novel targets for the new era of tumor immunotherapy. Innate immunity has been demonstrated to play a determinative role in the tumor microenvironment (TME) and influence the clinical outcomes of tumor patients. A thorough comprehension of the innate immune cells that infiltrate tumors would allow for the development of new therapeutics. In this review, we outline the role and mechanism of innate immunity in TME. Moreover, we discuss innate immunity-based cancer immunotherapy in basic and clinical studies. Finally, we summarize the challenges in sufficiently motivating innate immune responses and the corresponding strategies and measures to improve anti-tumor efficacy. This review could aid the comprehension of innate immunity and inspire the creation of brand-new immunotherapies for the treatment of cancer.

show abstract

Section: Cytokinesmentioning

confidence: 99%

Innate Immunity in Cancer Biology and Therapy

Zhang

Xue

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Activated cGAS-STING pathway in tumor cells lead to upregulation of various inflammatory genes, such as Type I interferon and impedes the neoplastic progression [9]. There are also related reports in AML, and therefore, many scientists have attempted to increase the expression of type I interferons by upregulating STING, thus achieving the goal of treating AML [10][11][12][13]. Yet, mounting evidence indicates that cGAS-STING pathway might provoke inflammation, leading to tumor transformation, development and metastasis in certain diseases [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Prognostic implications of cGAS and STING gene expression in acute myeloid leukemia

Chen,

Hong,

Chen

et al. 2024

Exp. Biol. Med.

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is one of the most threatening hematological malignances. cGAS-STING pathway plays an important role in tumor immunity and development. However, the prognostic role of cGAS-STING pathway in AML remains unknown. Firstly, The expression of cGAS and STING was analyzed by bioinformatics analysis. Subsequently, Bone marrow samples were collected from 120 AML patients and 15 healthy individuals in an independent cohort. The cGAS and STING expression was significantly elevated in AML patients compared with healthy controls. Patients with high cGAS and STING expression had a higher NRAS/KRAS mutation rate and lower complete remission (CR) rate. High cGAS and STING expression was significantly associated with lower overall survival (OS) and disease-free survival (DFS). Our findings revealed that the expression levels of cGAS and STING in AML are elevated. High expression of cGAS and STING correlated with worse OS and DFS and may be a useful biomarker for inferior prognosis in AML patients.

show abstract